Barclays PLC Has $189,000 Stock Holdings in Shattuck Labs, Inc. (NASDAQ:STTK)

Barclays PLC lifted its position in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 299.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,311 shares of the company’s stock after acquiring an additional 40,717 shares during the quarter. Barclays PLC owned approximately 0.11% of Shattuck Labs worth $189,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Shattuck Labs by 0.4% during the 3rd quarter. FMR LLC now owns 7,159,090 shares of the company’s stock valued at $24,985,000 after acquiring an additional 26,460 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Shattuck Labs by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock valued at $3,184,000 after acquiring an additional 8,133 shares in the last quarter. State Street Corp boosted its holdings in shares of Shattuck Labs by 7.8% during the 3rd quarter. State Street Corp now owns 766,410 shares of the company’s stock valued at $2,675,000 after acquiring an additional 55,579 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Shattuck Labs by 83.1% during the 2nd quarter. Renaissance Technologies LLC now owns 392,010 shares of the company’s stock valued at $1,513,000 after acquiring an additional 177,910 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Shattuck Labs by 44.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,228 shares of the company’s stock valued at $622,000 after acquiring an additional 54,505 shares in the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Insider Transactions at Shattuck Labs

In other news, Director Redmile Group, Llc bought 133,371 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The stock was acquired at an average cost of $1.25 per share, with a total value of $166,713.75. Following the transaction, the director now directly owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. This represents a 2.47 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Evercore ISI raised Shattuck Labs to a “strong-buy” rating in a research report on Wednesday, October 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. Finally, Citigroup lowered Shattuck Labs from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Four equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Shattuck Labs presently has a consensus rating of “Hold” and a consensus price target of $8.67.

Shattuck Labs Trading Up 3.6 %

STTK stock opened at $1.15 on Wednesday. The stock has a 50-day moving average price of $1.17 and a 200-day moving average price of $2.32. Shattuck Labs, Inc. has a 1-year low of $0.94 and a 1-year high of $11.76. The firm has a market cap of $54.90 million, a PE ratio of -0.75 and a beta of 1.71.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.